Erratum: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

被引：0
|
作者：
Russell P Rother
Scott A Rollins
Christopher F Mojcik
Robert A Brodsky
Leonard Bell
机构：
来源：
Nature Biotechnology | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nat. Biotechnol. 25, 1256–1264 (2007); published online 7 November 2007; corrected after print 7 December 2007 In the version of this article initially published, on p. 1258, paragraph 2, the incorrect serum concentrations to reach steady state and the incorrect accumulation ratio (Racc) for eculizumab were given.
引用
收藏
页码：1488 / 1488
相关论文
共 50 条
  • [31] Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
    Fassett, Michael J.
    Lopez, Adrian L. Hernandez
    CASE REPORTS IN WOMENS HEALTH, 2021, 30
  • [32] Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment
    Arcavi, Miriam
    Ceballo, Fernanda
    Caracciolo, Maria Beatriz
    Lazarowski, Alberto
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2020, 42 (03) : 335 - 340
  • [33] The complement in paroxysmal nocturnal hemoglobinuria
    PorcelPerez, JM
    RubioCaballero, MR
    REVISTA CLINICA ESPANOLA, 1996, 196 : 31 - 35
  • [34] EXTRAVASCULAR HEMOLYSIS DURING TREATMENT WITH ECULIZUMAB FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Graciaa, Sara
    Chonat, Satheesh
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [35] Eculizumab Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). the Argentinian Experience
    Brodsky, Andres L.
    Touliet, Valeria Soledad
    Rocaspana, Adriana
    Aldunate, Ximena
    Alzueta, Abel Esteban
    Barraza, Teresa
    Beguelin, Raul
    Carnpregher, Gabriel
    Beatriz Colin, Laura
    Dinardo, Pablo
    Gotta, Daniel
    Oliveira, Natalia
    Parodi, Claudia
    Perinotto, Gabriela
    Ramirez, Mario
    Rigada, Guillermina
    Ronzzetti, Rosanna
    Esther, Rosenfeld
    Blanca, Rossi
    Stivel, Miriam
    Zirone, Sandra
    BLOOD, 2015, 126 (23)
  • [36] Achievements and Limitations of Complement Inhibition by Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: The Role of Complement Component 3
    Risitano, A. M.
    Perna, F.
    Selleri, C.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2011, 11 (06) : 528 - 535
  • [37] Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial
    Yuzuru Kanakura
    Kazuma Ohyashiki
    Tsutomu Shichishima
    Shinichiro Okamoto
    Kiyoshi Ando
    Haruhiko Ninomiya
    Tatsuya Kawaguchi
    Shinji Nakao
    Hideki Nakakuma
    Jun-ichi Nishimura
    Taroh Kinoshita
    Camille L. Bedrosian
    Marye Ellen Valentine
    Gus Khursigara
    Keiya Ozawa
    Mitsuhiro Omine
    International Journal of Hematology, 2011, 93 : 36 - 46
  • [38] Eculizumab in paroxysmal nocturnal hemoglobinuria - The author replies
    Hillmen, Peter
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26): : 2787 - 2788
  • [39] Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria
    Zareba, Karolina M.
    DRUGS OF TODAY, 2007, 43 (08) : 539 - 546
  • [40] Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
    Marti-Carvajal, Arturo J.
    Anand, Vidhu
    Felipe Cardona, Andres
    Sola, Ivan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
12345